INFORMATION FOR PATIENTS SECTION.

Information for patients. The patient should be told to:Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.Keep Naftin(R) Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes.. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.. Keep Naftin(R) Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes.

PHARMACOKINETICS SECTION.

Pharmacokinetics. In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.Following single topical application of 1% of naftifine cream to the skin of healthy subjects, systemic absorption of naftifine was approximately 6% of the applied dose. Following single topical applications of 3H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with half-life of approximately two to three days.

INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE. Naftin(R) Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Naftin(R) Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsuransEfficacy for this organism in this organ system was studied in fewer than 10 infections. Epidermophyton floccosum.

ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. During clinical trials with Naftin(R) Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin(R) Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

Carcinogenesis, mutagenesis, impairment of fertility. Long-term studies to evaluate the carcinogenic potential of Naftin(R) Cream and Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility.

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY. Naftifine Hydrochloride is synthetic allylamine derivative. The following in vitro data are available but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against broad spectrum of organisms, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini, and microsporum gypseum, and fungistatic activity against Candida species, including Candida albicans. Naftin(R) Cream and Gel, 1% have only been shown to be clinically effective against the disease entities listed in the INDICATIONS AND USAGE section.Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and corresponding accumulation of squalene in the cells.. Pharmacokinetics. In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.Following single topical application of 1% of naftifine cream to the skin of healthy subjects, systemic absorption of naftifine was approximately 6% of the applied dose. Following single topical applications of 3H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with half-life of approximately two to three days.

DESCRIPTION SECTION.

DESCRIPTION. Naftin(R) Cream, 1% and Naftin(R) Gel, 1% contain the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin(R) Cream and Gel, 1% are for topical use only.. CHEMICAL NAME. (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride. Naftifine hydrochloride has an empirical formula of C21H21NoHCl and molecular weight of 323.86.. Contains. Active Ingredient:Naftifine hydrochloride.......... 1%.Inactive Ingredients: Naftin(R) Cream, 1% contains benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol. Hydrochloric acid may be added to adjust pH. Naftin(R) Gel, 1% contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.. Chemical Structure.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. sufficient quantity of Naftin(R) Cream, 1% should be gently massaged into the affected and surrounding skin areas once day. sufficient quantity of Naftin(R) Gel, 1% should be gently massaged into the affected and surrounding skin areas twice day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin(R) Cream or Gel, 1%, the patient should be re-evaluated.

GENERAL PRECAUTIONS SECTION.

General. Naftin(R) Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin(R) Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of mounting of infected tissue in solution of potassium hydroxide or by culture on an appropriate medium.

HOW SUPPLIED SECTION.

HOW SUPPLIED. Naftin(R) (naftifine hydrochloride) Cream. 1% is supplied in collapsible tubes in the following sizes: 60g NDC 0259-4126-60 90g NDC 0259-4126-90Naftin(R) (naftifine hydrochloride) Gel, 1% is supplied in collapsible tubes in the following sizes: 40g NDC 0259-4770-40 60g NDC 0259-4770-60 90g NDC 0259-4770-90. 60g NDC 0259-4126-60. 90g NDC 0259-4126-90. 40g NDC 0259-4770-40. 60g NDC 0259-4770-60. 90g NDC 0259-4770-90. Note: Store Naftin(R) Cream, 1% below 30C (86F).Store Naftin(R) Gel, 1% at room temperature.

PRECAUTIONS SECTION.

PRECAUTIONS. General. Naftin(R) Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin(R) Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of mounting of infected tissue in solution of potassium hydroxide or by culture on an appropriate medium.. Information for patients. The patient should be told to:Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.Keep Naftin(R) Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes.. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.. Keep Naftin(R) Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes.. Carcinogenesis, mutagenesis, impairment of fertility. Long-term studies to evaluate the carcinogenic potential of Naftin(R) Cream and Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility.. Pregnancy. Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.. Nursing mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin(R) Cream or Gel,1 are administered to nursing woman.. Pediatric use. Safety and effectiveness in pediatric patients have not been established.

PREGNANCY SECTION.

Pregnancy. Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

TERATOGENIC EFFECTS SECTION.

Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.